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OBJECTIVE — To examine uric acid (UA) as a possible predictor of the progression of
coronary artery calciﬁcation (CAC) using data from the prospective Coronary Artery Calciﬁca-
tion in Type 1 Diabetes (CACTI) Study.
RESEARCH DESIGN AND METHODS — CAC was measured by electron beam to-
mographyatthebaselineandatafollow-up6.00.5yearslater.Thestudypopulationincluded
443 participants with type 1 diabetes and 526 control subjects who were free of diagnosed
coronary artery disease at baseline. The presence of renal disease was deﬁned by the presence of
albuminuria and/or low glomerular ﬁltration rate.
RESULTS — In subjects without renal disease, serum UA predicted CAC progression (odds
ratio 1.30 [95% CI 1.07–1.58], P  0.007) independent of conventional cardiovascular risk
factors including diabetes and the presence of metabolic syndrome.
CONCLUSIONS — SerumUAlevelspredicttheprogressionofcoronaryatherosclerosisand
may be useful in identifying who is at risk for vascular disease in the absence of signiﬁcant
chronic kidney disease.
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E
levated serum uric acid (UA) is asso-
ciated with kidney disease, but it has
also been linked to endothelial dys-
function and development of hyperten-
sionirrespectiveofrenalinvolvement(1).
UA may contribute to the atherosclerotic
process through induction of endothelial
dysfunction (2) and inﬂammation (3).
SerumUAlevelshavebeencorrelated
with negative cardiovascular outcomes in
the general population (4) and type 2 di-
abetic subjects (5) and predict the pro-
gression of diabetic nephropathy (6) in
type 1 diabetic subjects. The objective of
this study was to evaluate UA levels as a
predictor of subclinical atherosclerosis
progression in the Coronary Artery Calci-
ﬁcation in Type 1 Diabetes (CACTI)
Study.
RESEARCH DESIGN AND
METHODS— Of the 1,416 individu-
als asymptomatic for coronary artery dis-
ease (CAD) enrolled at baseline, 1,022
had data on coronary artery calciﬁcation
(CAC) progression. Subjects with coro-
nary events during follow-up (n  18)
andincompleteinformationaboutcovari-
ates (n  35) were excluded, resulting in
969 subjects. Clinical and laboratory
evaluations were performed as previously
described (7). CAC was measured twice
and averaged at the baseline and at fol-
low-up 6.0  0.5 years later. CAC pro-
gressors were deﬁned as participants
whose square root-transformed CAC vol-
ume (CVS) increased by 2.5 mm (8).
Serum UA levels were measured at base-
line on the clinical analyzer utilizing a
uricase-based commercial kit. Nor-
moalbuminuria was deﬁned as overnight
albumin excretion rate 20 g/min or
urinary albumin-to-creatinine ratio 30
mg/g. Glomerular ﬁltration rate (GFR)
was estimated by the Mayo Clinic qua-
dratic equation (GFRMC) (9). Metabolic
syndrome(MetS)wasdeﬁnedbytheorig-
inal Adult Treatment Panel III (ATP III)
criteria (10). The study protocol was ap-
proved by the Colorado Combined Insti-
tutional Review Board, and informed
consent was obtained from all
participants.
Statistical analysis
Serum UA, creatinine, cystatin C, and al-
bumin-to-creatinine ratio were log-
transformed. We deﬁned normal renal
status as a GFRMC 60 ml/min per 1.73
m
2 and normoalbuminuria, and chronic
kidney disease (CKD) as GFRMC 60
ml/min per 1.73 m
2 and/or albuminuria.
Stepwise multiple regression analysis
was performed to select predictors of
CAC progression (Model 1). Renal status
was added to this model and interactions
between renal status and each variable
were tested. SAS 9.2 (SAS Institute, Cary,
NC) was used for these analyses.
RESULTS— Subjects with signiﬁcant
progression of CAC (n  338) were older
andhadhigherCACatbaselinethannon-
progressors. Serum UA levels were also
higher in progressors (5.6 [4.9–6.5 mg/
dl]) than in nonprogressors (5.1 [4.4–
5.9], P  0.0001).
Baseline characteristics of partici-
pants by renal status are displayed in Ta-
ble 1. Among subjects with normal renal
function, CAC progressed in 263/864
(30%). In subjects with CKD, 75/105
(71.4%) progressed. Age, higher CVS at
baseline, and the use of ACE inhibitors or
angiotensinreceptorblockersweresignif-
icantly associated with progression. Sub-
jects with CKD had higher UA levels (5.9
[5.1–7.0 mg/dl]) than subjects with nor-
mal renal status (5.2 [4.56.1], P 
0.0001), and this association was not
modiﬁed by diabetes status.
In stepwise regression, age, sex, type
1 diabetes, baseline CVS, hypertension,
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terol, and serum UA were retained.
HigherbaselineserumUApredictedCAC
progression (odds ratio [OR] 1.30 for
each 1 SD change [0.2 mg], [95% CI
1.07–1.58], P  0.007).
To explore if UA predicted CAC pro-
gression independently of CKD, interac-
tion terms between renal status and all
covariates were entered. The effects of sex
(P  0.01 for the interaction), baseline
CVS (P  0.003), and UA (P  0.01)
differed signiﬁcantly by renal status. In
subjects with normal renal status, all vari-
ables selected from Model 1 were signiﬁ-
cantly associated with CAC progression,
including UA (OR 1.25 [95% CI 1.01–
1.54], P  0.03). In subjects with CKD,
UA was not a predictor of CAC (0.98
[0.55–1.74], P  0.96). The addition of
MetS, alcohol intake, thiazides, ACEs, or
angiotensin receptor blockers to the
model did not substantially change the
results about UA and the outcome.
CONCLUSIONS— The novel ﬁnd-
ing of this study is that UA levels predict
CAC progression independently of other
established CVD risk factors. In contrast
to previous studies associating UA with
mortality (3,5), in this report we exam-
ined an established marker of coronary
plaque burden, allowing for the explora-
tion of early events related to the progres-
sion of coronary lesions. Fukui et al. (11)
reported an association between higher
serum UA and greater intima-media
thickness and lower ankle-brachial index
inpatientswithtype2diabetes.However,
this is the ﬁrst report of an independent
association of UA levels on the progres-
sion of coronary atherosclerosis.
The only previous study to examine
an association between UA and CAD in
type 1 diabetes (12) found that hyperuri-
cemia was correlated with the presence of
CAD in women but not in men, and that
this association was independent of hy-
Table 1—Clinical and laboratory characteristics at baseline between progressors and nonprogressors by renal status
Normal renal status Signiﬁcant CKD
Progressors
n  263
Nonprogressors
n  601 P
Progressors
n  75
Nonprogressors
n  30 P
Age (years) 42  83 7  8 0.0001 41  83 5  8 0.0005
Male (%) 64 38 0.0001 62 70 0.47
Type 1 diabetes (%) 47 40 0.03 80 63 0.07
Smoking current (%) 12 7 0.03 11 10 0.90
Smoking ever (%) 22 19 0.31 29 20 0.31
Hypertension (%) 24 9 0.0001 47 31 0.13
Systolic BP (mmHg) 119  13 112  11 0.0001 122  14 121  14 0.82
Diastolic BP (mmHg) 80  97 6  7 0.0001 80  10 81  10 0.81
Baseline square root CAC volume 3.5  5.9 0.22  1.0 0.0001 5.5  9.0 0.9  2.4 0.006
BMI (kg/m
2) 27  42 5  4 0.0001 26  42 7  4 0.82
Waist circumference (cm)
Male 96  11 88  10 0.0001 93  10 91  11 0.56
Female 84  13 78  11 0.0001 84  14 78  12 0.42
Waist-to-hip ratio
Male 0.90  0.06 0.86  0.06 0.0001 0.89  0.05 0.88  0.05 0.30
Female 0.78  0.06 0.76  0.06 0.002 0.79  0.07 0.79  0.07 0.97
Uric acid (mg/dl)
Male 5.9 (5.2–6.8) 5.8 (5.2–6.4) 0.42 6.2 (5.4–7.3) 6.5 (5.6–7.7) 0.32
Female 4.8 (4.2–5.4) 4.5 (4.0–5.1) 0.01 5.3 (4.6–5.8) 5.0 (4.5–5.9) 0.52
Total cholesterol (mg/dl) 183  36 183  36 0.27 184  35 179  41 0.76
HDL (mg/dl) 49  14 55  16 0.0001 53  16 49  14 0.29
LDL (mg/dl) 111  32 106  32 0.03 107  30 107  31 0.88
Triglycerides (mg/dl) 105 (73–149) 90 (64–121) 0.0001 96 (62–138) 107 (71–139) 0.41
A1C (%)
Type 1 diabetes 7.8  1.1 7.7  1.2 0.85 8.3  1.3 7.9  0.9 0.20
Control subjects 5.6  0.4 5.4  0.3 0.0001 5.8  0.5 5.4  0.4 0.03
Serum creatinine (mg/dl) 1.1 (1.1–1.3) 1.1 (1.0–1.3) 0.009 1.3 (1.1–1.5) 1.4 (1.2–1.8) 0.18
Cystatin C (mg/l) 0.78 (0.72–0.84) 0.76 (0.69–0.82) 0.007 0.95 (0.79–0.96) 0.92 (0.76–1.03) 0.84
ACR (mg/g creatinine) 4.8 (3.2–6.6) 4.4 (3.2–5.7) 0.03 59.7 (26–179) 51 (15–276) 0.69
ACE inhibitors/ARB use (%) 16 8 0.001 57 20 0.0005
Thiazide diuretic use (%) 5 2.3 0.04 18 3 0.001
Statin use (%) 17 5 0.0001 25 10 0.08
Alcohol intake positive (%) 79 77 0.86 59 75 0.05
Number of alcohol drinks/month 21  35 15  25 0.02 11  21 11  18 0.90
MetS (%) 18.2 8.3 0.0001 30.6 13.3 0.06
Data are means  SD, %, or geometric means (interquartile range). Any alcohol intake is deﬁned as 12 or more drinks during their lifetime. Drinks per month are
a combination of standard amounts of beer (12 oz.), wine (3.5 oz.), or hard liquor (1.5 oz.). ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blockers;
BP, blood pressure.
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published data by our group that show
baseline serum UA predicts the develop-
ment of microalbuminuria after 6 years
(13), and Hovind et al. (6) observed that
elevated serum UA levels are associated
with the development of macroalbumin-
uria. Rosolowsky et al. (14) reported an
association between serum UA and im-
paired GFR in microalbuminuric and
normoalbuminuric type 1 diabetic sub-
jects. Experimental information suggests
that UA may mediate the development of
both hypertension and renal disease by
dysfunction of endothelial and vascular
smoothmusclecellsresultinginoxidative
stress, a reduction in endothelial nitric
oxide, and activation of the renin-
angiotensin system (15).
We found that UA levels predict CAC
progression only in subjects with normal
renal function. While UA levels may rise
secondary to a fall in GFR, our ﬁndings
suggest that the temporal relation be-
tween the elevation of UA levels and CAC
progression is not simply a consequence
of declining renal function. As CKD ad-
vances, other factors may play a more
prominentroleinvasculardiseasesuchas
CKD-associated mineral and bone
disorders.
Hyperuricemia is more often seen in
people with MetS and has been put for-
ward as one of the criteria of the syn-
drome (1). Our study demonstrated that
UA predicted CAC progression indepen-
dent of the presence of MetS in subjects
without renal disease.
Serum UA level should be considered
a marker of increased CAD risk in sub-
jects with and without type 1 diabetes in
the absence of signiﬁcant kidney disease.
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